Despite concerns about the efficacy and safety of checkpoint inhibitors, many biotech companies are advancing them in clinical trials to treat cancer. By 2032, the market for these drugs could reach nearly $189.4 billion. While these inhibitors have shown dramatic results in some cancer patients, they only seem to work for a small percentage. As a result, research is shifting towards combining them with other cancer treatments, and exploring potential new inhibitors. These advances are expected to revolutionize cancer care.
The NHS needs to tighten its third-party supplier cybersecurity
The NHS should proactively fortify cybersecurity within its third-party software suppliers following recent damaging ransomware attacks, says Jonathan Lee from Trend Micro. He suggests implementing
